David Savello

Dr. Savello, a Founder and Partner in NDA Partners, is a senior pharmaceutical executive with extensive experience in development strategy and CMC. He formerly served as Senior Vice President for Development Operations at XenoPort, Inc. and Executive Vice President and Chief Scientific Officer for Cardinal Health. He also served in executive management positions at Glaxo and Glaxo Wellcome as Vice President for North American Regulatory Affairs and Vice President of Drug Development. While at Glaxo and Glaxo Wellcome, he was responsible for the development, regulatory submission, and approval of a number of products, including Serevent®, Flovent®, Flonase®, Imitrex®, Epivirv, Zofran®, and Zantac® Rx to OTC switch. He also held R&D management and executive management positions at Boehringer Ingelheim and 3M Riker Laboratories.

Dr. Savello currently serves on the University of California, San Francisco Translational Medicine Advisory Board and as a Venture Advisor and Scientific Advisory Board member of Pappas Capital.